Suppr超能文献

辛伐他汀对肾病综合征患者血脂、脂蛋白浓度及低密度脂蛋白代谢的影响。

Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.

作者信息

Warwick G L, Packard C J, Murray L, Grierson D, Stewart J P, Shepherd J, Boulton-Jones J M

机构信息

Renal Unit, Royal Infirmary, Glasgow, U.K.

出版信息

Clin Sci (Lond). 1992 Jun;82(6):701-8. doi: 10.1042/cs0820701.

Abstract
  1. The effect of inhibiting the rate-limiting enzyme (3-hydroxy-3-methylglutaryl-CoA reductase, EC 1.1.1.88) in cholesterol synthesis on plasma lipid and lipoprotein concentrations was investigated in 16 patients with primary glomerular disease, heavy proteinuria, well-preserved renal function and hypercholesterolaemia. 2. Detailed studies of low-density lipoprotein metabolism were performed on eight patients before and after 12 weeks of simvastatin therapy. Radioiodinated tracers were used to quantify the fractional catabolic rate of low-density lipoprotein by apolipoprotein B/E receptors and alternative pathways. 3. Simvastatin produced consistent reductions in total plasma cholesterol concentration (median 36.9%), plasma low-density lipoprotein-cholesterol concentration (43.6%) and apolipoprotein B pool size (29.9%). 4. In contrast, the changes in kinetic parameters of low-density lipoprotein metabolism showed no clear pattern. Although an increase in the receptor-mediated catabolism of low-density lipoprotein was demonstrated in five patients, no change or a slight decrease was seen in three patients. Production rates were not significantly altered, although there was a slight decrease in the median value (from 12.4 to 9.7 mg day-1 kg-1). Plasma lathosterol concentration was reduced in all eight patients (range 34-71%), indirectly confirming significant inhibition of cholesterol synthesis. 5. These results suggest that, as in patients with primary moderate hyperlipidaemia, the significant cholesterol-lowering effect of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in the nephrotic syndrome is accompanied by variable changes in lipoprotein metabolism. The reasons for this heterogeneous response are unclear. This reflects our limited understanding of the metabolic basis of nephrotic hyperlipidaemia and the relationship between hepatic sterol synthesis and plasma lipoprotein kinetics.
摘要
  1. 在16例原发性肾小球疾病、重度蛋白尿、肾功能良好且患有高胆固醇血症的患者中,研究了抑制胆固醇合成中的限速酶(3-羟基-3-甲基戊二酰辅酶A还原酶,EC 1.1.1.88)对血浆脂质和脂蛋白浓度的影响。2. 对8例患者在辛伐他汀治疗12周前后进行了低密度脂蛋白代谢的详细研究。使用放射性碘标记的示踪剂通过载脂蛋白B/E受体和替代途径定量低密度脂蛋白的分解代谢率。3. 辛伐他汀使血浆总胆固醇浓度(中位数降低36.9%)、血浆低密度脂蛋白胆固醇浓度(降低43.6%)和载脂蛋白B池大小(降低29.9%)持续下降。4. 相比之下,低密度脂蛋白代谢动力学参数的变化没有明显规律。虽然在5例患者中证明了低密度脂蛋白受体介导的分解代谢增加,但在3例患者中未见变化或略有下降。生成率没有显著改变,尽管中位数略有下降(从12.4降至9.7 mg·天⁻¹·kg⁻¹)。所有8例患者的血浆羊毛甾醇浓度均降低(范围为34 - 71%),间接证实了胆固醇合成受到显著抑制。5. 这些结果表明,与原发性中度高脂血症患者一样,3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂在肾病综合征中显著的降胆固醇作用伴随着脂蛋白代谢的可变变化。这种异质性反应的原因尚不清楚。这反映了我们对肾病性高脂血症代谢基础以及肝脏甾醇合成与血浆脂蛋白动力学之间关系的理解有限。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验